enGene’s (ENGN) Outperform Rating Reaffirmed at Oppenheimer

enGene (NASDAQ:ENGN)‘s stock had its “outperform” rating reiterated by analysts at Oppenheimer in a research note issued on Tuesday, Benzinga reports. They currently have a $30.00 price objective on the stock. Oppenheimer’s price target would suggest a potential upside of 368.02% from the company’s previous close.

Separately, Morgan Stanley reaffirmed an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $33.67.

enGene Trading Down 11.1 %

NASDAQ:ENGN opened at $6.41 on Tuesday. The firm has a 50 day moving average of $7.24 and a 200 day moving average of $11.03. The company has a quick ratio of 42.80, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. enGene has a 52 week low of $4.94 and a 52 week high of $43.00. The stock has a market capitalization of $283.10 million, a price-to-earnings ratio of -3.86 and a beta of -0.68.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. As a group, sell-side analysts anticipate that enGene will post -1.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Logos Global Management LP boosted its position in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares during the last quarter. SR One Capital Management LP acquired a new stake in enGene during the 2nd quarter valued at approximately $4,715,000. Janus Henderson Group PLC purchased a new stake in shares of enGene in the 1st quarter valued at $17,095,000. Altitude Crest Partners Inc. acquired a new stake in shares of enGene in the first quarter worth $2,039,000. Finally, Omega Fund Management LLC purchased a new position in shares of enGene during the fourth quarter worth $10,441,000. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.